Albany Molecular Research, Inc. Renews Relationship with Eli Lilly and Company
Albany Molecular Research, Inc. announced a new drug discovery research agreement with Eli Lilly and Company, continuing an ongoing relationship between the two companies that began in 1998. Under the terms of the agreement, AMRI will provide fee-for-service chemistry research on projects in strategic therapeutic areas identified by Lilly. Though specific financial details were not disclosed, the contract includes fee-for-service provisions and is a continuation of a recently expired agreement.
"We believe that Lilly's decision to continue this significant relationship with AMRI reflects the value that AMRI's scientists have been able to bring to the collaboration," said AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
New rare-earth superconductors
Innovative Technology and Environment-friendly Trends Drive the Market for Chemicals Used in Transportation
Water treatment: Arkema and Polymem join forces to market a new ultrafiltration membrane technology
FMC Increases Soda Ash Prices
BP Pledges $100 Million to UK-Led Universities to Create Industry-Changing Materials
LyondellBasell's World-Class PE and PP Technologies Selected by Kazakhstan Petrochemical Industries
An inexpensive 'dipstick' test for pesticides in foods
Dow Corning to purchase U.S. Silicon metal producer
Kemira has opened a sales office for water-treatment chemicals in Lithuania
BASF plans changes to its butanediol value chain and plasticizers business
Uvinul 4050 H from BASF is the first light stabilizer in its class to obtain FDA approval for use in plastics
